Pulmonary Pharmacology & Therapeutics

Papers
(The TQCC of Pulmonary Pharmacology & Therapeutics is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study39
Celebrating the appointment of Mario Cazzola as Honorary Editor of Pulmonary Pharmacology & Therapeutics34
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies29
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)28
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d26
S1PR1 attenuates pulmonary fibrosis by inhibiting EndMT and improving endothelial barrier function21
Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation20
Pharmacokinetic variability of CFTR modulators from standard and alternative regimens19
Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential18
Editorial Board18
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients18
Editorial Board16
Exploring the role of β2- and β3-adrenergic receptors in cystic fibrosis14
Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma14
Chronic obstructive pulmonary disease and emerging ER stress-related therapeutic targets14
The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study13
Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea12
FTO regulates the proliferation and apoptosis of pulmonary artery smooth muscle cells through m6A demethylation modification12
Real-life impact of genotype and severity of lung disease on efficacy of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis12
Ferroptosis mediates airway epithelial E-cadherin dysfunction in LPS-induced acute lung injury12
Effects of corticosteroids on Covid-19 patients: A systematic review and meta-analysis on clinical outcomes12
Impact on beclometasone dipropionate pharmacokinetics when switching to a low global warming potential propellant in a pressurised metered-dose inhaler11
Triple inhaled therapy in asthma: Beliefs, behaviours and doubts11
Patients with moderate to severe COVID-19 outcomes on remdesivir according to baseline 4C mortality score11
Unveiling the protective role of sevoflurane in video-assisted thoracoscopic surgery associated-acute lung injury: Inhibition of ferroptosis11
The era of multiple biologics: Is combination and switching an option in the management of severe asthma?10
Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant10
Editorial Board10
Editorial Board10
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study10
Efficacy and safety of sequential combination therapy for pulmonary arterial hypertension: A meta-analysis of Randomized-Controlled Trials10
Editorial Board9
Strongyloides venezuelensis-derived venestatin ameliorates asthma pathogenesis by suppressing receptor for advanced glycation end-products-mediated signaling9
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis9
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics9
Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality9
Ensifentrine approval: A milestone in the treatment of COPD9
Corrigendum to “Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients 9
Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study9
Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea8
Protective effects of adipose-derived biogenic nanoparticles on the pulmonary microvascular endothelial barrier in mice with ventilator-induced lung injury via the TRPV4/ROCK1 signalling pathway8
Bispecific domain antibody attenuates airway hyperresponsiveness and pulmonary inflammation in ovalbumin-lipopolysaccharide induced asthma model by inhibiting IL-23 and TNF-α8
Remote preconditioning combined with nebulized budesonide alleviate lipopolysaccharide induced acute lung injury via regulating HO-1 and NF-κB in rats8
The wonders of stem cells therapeutic application towards chronic obstructive pulmonary disease8
Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan7
Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany7
Repeated doses of captopril induce airway hyperresponsiveness by modulating the TRPV1 receptor in rats7
Editorial Board7
Drug-drug interactions in vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor-ivacaftor7
β-sitosterol targets glucocorticoid receptor to reduce airway inflammation and remodeling in allergic asthma7
Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma7
Tyvaso DPI: Drug-device characteristics and patient clinical considerations7
0.12597894668579